SCHEMBL4680796

SCHEMBL4680796

CN1CCCC[C@H]1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283488 1.00 — —
SCHEMBL2421142 1.00 — —
SCHEMBL25262256 1.00 CYP1A2 (0.55) —
Hydrochloric Acid SCHEMBL11468862 0.98 CYP1A2 (0.53) —
SCHEMBL7279980 0.98 CYP1A2 (0.59) —
SCHEMBL84792 0.93 — —
SCHEMBL178545 0.93 — —
SCHEMBL26011205 0.93 — —
SCHEMBL1086946 0.93 — —
SCHEMBL30917693 0.93 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079853-A N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases — 2026-05-26 — — CN disclosed
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 — — US disclosed
US-20250206745-A1 PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES NODTHERA LTD (GB) 2025-06-26 — — US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 — — EP disclosed
US-20250145639-A1 MUTANT KRAS MODULATORS AND USES THEREOF NEWAVE PHARMACEUTICAL INC (US) 2025-05-08 — — US disclosed
WO-2025087431-A1 PAN-KRAS INHIBITOR AND USE THEREOF IN MEDICINES 贝达药业股份有限公司 2025-05-01 — — WO disclosed
US-12139499-B2 Heteroaryl compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2024-11-12 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
EP-4349828-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Yingli Pharmaceutical Co. Ltd. (CN) 2024-04-10 — — EP disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
EP-1333834-B1 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2008-04-23 — — EP disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 — — US disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 — — US disclosed
US-20070135464-A1 Antiinflammation agents AMGEN, INC. 2007-06-14 — — US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 — — US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 — — US disclosed
US-7186841-B2 (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders AMGEN INC. (US) 2007-03-06 — — US disclosed
US-20050043330-A1 Antiinflammation agents AMGEN INC. (US) 2005-02-24 — — US disclosed
US-6846834-B2 Compounds contain fused carbocyclic or heterocyclic rings; modulate expression and/or function of proteins involved in inflammation, metabolism and cell proliferation AMGEN INC. (US) 2005-01-25 — — US disclosed
WO-2005002577-A1 DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA F. HOFFMANN-LA ROCHE AG (CH) 2005-01-13 — — WO disclosed
Send feedback